



DEPARTMENT OF THE ARMY
U.S. ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES
FORT DETRICK, FREDERICK, MARYLAND 21701-5011

January 31, 1989

REPLY TO
ATTENTION OF:

Deputy for Science

Mr. J. A. Matji
General Manager
Andromaco, S.A. Laboratories
Azcona 31
28028 Madrid, Spain

Dear Mr. Matji

I have enclosed the results of our extensive testing in vivo of the AM3, AM5, AM6, AM7, and AM8 compounds. As you can see from the reports, AM3 shows promising results as a potential antiviral agent. We are presently having them tested in the human immunodeficiency virus (HIV) assay in vitro. In addition, we will test AM3 and AM5 further in the mouse AIDS animal model.

The data shows also that AM5 has good antiviral activity and we plan to pursue further studies with AM5 also.

AM6, 7 and 8 did not demonstrate antiviral activity.

Based on the enclosed data we will conduct further in vitro and in vivo testing of AM3 and AM5.

Our current supply of AM3 is adequate, however, we have little AM5 left. If available, can you supply us with additional AM5 (15 or 20 grams)?

As the data on further testing with AM3 becomes available, I will sent it to you as soon as possible.

I am sorry for the long delay in getting this information to you.

Best regards.

Sincerely yours,

Michael A. Chirigos,
Ph.D., D.Sc.
Deputy for Science

Enclosure

FUNDACIÓ
RUBIÓ